Christina Rossi
Net worth: - $ as of 31/05/2026
Net worth: - $ as of 31/05/2026
Christina Rossi is currently Director at CG Oncology, Inc. since 2025.
Former roles include Independent Director at Xilio Therapeutics, Inc. from 2021 to 2026; Chief Operating Officer at Blueprint Medicines Corp.
from 2022 to 2025; Head-Multiple Sclerosis Business Unit at Genzyme Corp.
from 2012 to 2018; Head-Multiple Sclerosis Business North America at Genzyme Therapeutics Ltd. from 2016 to 2018; and Head-Commercial Strategy at Eidetica Biopharma GmbH from 2005 to 2010.
Education includes an undergraduate degree from Duke University in 1997 and an MBA from Harvard Business School in 2003.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CG ONCOLOGY, INC. -.--% | 04/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| 02/01/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| CG ONCOLOGY, INC. | Director/Board Member | 24/11/2025 |
| Companies | Position | End |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Director/Board Member | 15/04/2026 |
| BLUEPRINT MEDICINES CORPORATION | Chief Operating Officer | 01/01/2025 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01/10/2018 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | 01/10/2018 |
Eidetica Biopharma GmbH
Eidetica Biopharma GmbH Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceutical drugs | Corporate Officer/Principal | 01/01/2010 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 8 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Blueprint Medicines Corp.
Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
CG Oncology, Inc.
CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Eidetica Biopharma GmbH
Eidetica Biopharma GmbH Pharmaceuticals: MajorHealth Technology Develops and manufactures biopharmaceutical drugs | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Select your edition
All financial news and data tailored to specific country editions